We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
-3.13%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$532M
AUM Growth
-$39.7M
Cap. Flow
-$48.9M
Cap. Flow %
-9.2%
Top 10 Hldgs %
60.26%
Holding
28
New
1
Increased
10
Reduced
13
Closed
2

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$11.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$5.93M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.29M
4
ABT icon
Abbott
ABT
+$4.12M
5
ELV icon
Elevance Health
ELV
+$2.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.1M
2
EXEL icon
Exelixis
EXEL
+$15.7M
3
LLY icon
Eli Lilly
LLY
+$11.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.69M
5
BAX icon
Baxter International
BAX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 98.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.05T
$49.1M 9.23%
667,050
-157,400
-19% -$11.7M
BAX icon
2
Baxter International
BAX
$11.7B
$42.2M 7.95%
952,833
-126,400
-12% -$5.84M
ABT icon
3
Abbott
ABT
$175B
$37.5M 7.06%
976,590
+104,000
+12% +$4.12M
RVTY icon
4
Revvity
RVTY
$12.3B
$32.5M 6.12%
623,408
+7,980
+1% +$417K
IRWD icon
5
Ironwood Pharmaceuticals
IRWD
$635M
$30.2M 5.67%
2,355,378
+14,484
+0.6% +$183K
BSX icon
6
Boston Scientific
BSX
$65.4B
$27.2M 5.11%
1,255,580
+700
+0.1% +$15.3K
BMY icon
7
Bristol-Myers Squibb
BMY
$124B
$26.3M 4.94%
449,290
-158,900
-26% -$8.69M
GILD icon
8
Gilead Sciences
GILD
$167B
$25.7M 4.84%
359,290
-5,700
-2% -$424K
SHPG
9
DELISTED
Shire pic
SHPG
$25M 4.71%
146,961
+62,500
+74% +$11.1M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$24.6M 4.63%
333,950
+65,070
+24% +$5.29M
IART icon
11
Integra LifeSciences
IART
$1.5B
$24.1M 4.54%
562,414
-50,000
-8% -$2.03M
MASI
12
DELISTED
Masimo
MASI
$21.1M 3.97%
313,004
-43,219
-12% -$2.66M
BIO icon
13
Bio-Rad Laboratories Class A
BIO
$8.15B
$20.8M 3.91%
114,042
-18,542
-14% -$3.16M
ELV icon
14
Elevance Health
ELV
$80.9B
$20.2M 3.81%
140,810
+17,960
+15% +$2.4M
MRK icon
15
Merck
MRK
$315B
$16.7M 3.14%
297,014
-36,260
-11% -$2.12M
MCK icon
16
McKesson
MCK
$98.5B
$16.2M 3.04%
115,200
-16,460
-13% -$2.42M
PDCO
17
DELISTED
Patterson Companies, Inc.
PDCO
$15.8M 2.98%
386,232
+40,440
+12% +$1.74M
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$12.9M 2.42%
855,265
-103,614
-11% -$1.37M
CI icon
19
Cigna
CI
$74.5B
$12.7M 2.39%
95,270
-16,800
-15% -$2.2M
UTHR icon
20
United Therapeutics
UTHR
$22.7B
$9.75M 1.83%
67,974
-15,500
-19% -$1.98M
LPNT
21
DELISTED
LifePoint Health, Inc.
LPNT
$9.36M 1.76%
164,714
– –
EXEL icon
22
Exelixis
EXEL
$14.1B
$7.75M 1.46%
520,091
-1,090,400
-68% -$15.7M
ACH
23
Accendra Health
ACH
$266M
$7.56M 1.42%
214,172
+3,000
+1% +$101K
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
$6.61M 1.24%
499,153
+89,189
+22% +$1.52M
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
$5.93M 1.12%
+48,500
New +$5.93M
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q4 2016 Portfolio in Review

As of Q4 2016, Sector Gamma AS held 28 positions worth $532M, down 6.9% from $571M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sector Gamma AS withdrew a net $48.9M in Q4 2016, closing 2 positions and reducing 13 holdings. Its most notable exit was Biogen, an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Sector Gamma AS opened a new position in Alexion Pharmaceuticals worth $5.93M.

  • Sector Gamma AS's largest Q4 2016 buy was Alexion Pharmaceuticals: 48,500 shares worth $5.93M.
  • Sector Gamma AS added most to Shire pic in Q4 2016, an estimated $11.1M increase.
  • Sector Gamma AS's biggest Q4 2016 reduction was Exelixis, cutting an estimated $15.7M.
  • Sector Gamma AS fully exited Biogen in Q4 2016, selling an estimated $21.1M.
  • Sector Gamma AS's ten largest holdings make up 60% of its $532M portfolio in Q4 2016.
  • Sector Gamma AS opened 1 new position and closed 2 in Q4 2016.
  • Sector Gamma AS's portfolio value fell 6.9% quarter-over-quarter to $532M.

Based on Sector Gamma AS's 13F filing for Q4 2016, filed 14 Feb 2017.